July 17, 2024
5 min watch
Save
VIDEO: Stopping enzalutamide has little effect on prostate cancer quality of life
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Stephen Freedland, MD, discusses the results of the EMBARK study into high-risk, nonmetastatic biochemically recurrent prostate cancer, which he co-presented at ASCO Annual Meeting.
Freedland, a urologist at Cedars-Sinai Medical Center, highlighted the study, which examined the use of enzalutamide in patients with prostate cancer, focusing specifically on the quality- of-life data.
“By and large, the short answer we saw is we looked at many different domains and we really saw no impact on quality of life of stopping treatment,” Freedland said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Freedland reports consulting and funding from Astellas Pharma, AstraZeneca, Bayer, Clovis Oncology, Dendreon, Diasorin, Exact Sciences, Ferring, GenomeDx, Genomic Health, Janssen Biotech, MDxHealth, Merck, Myovant Sciences, Myriad Genetics, OPKO Diagnostics, Pfizer, Progenika and Sanofi.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.